Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306730 | PMC |
| http://dx.doi.org/10.1016/j.annemergmed.2020.06.038 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trial.
EClinicalMedicine
January 2025
Janssen Research and Development, Beerse, Belgium.
Background: Vaccine co-administration can increase vaccination coverage. We assessed the safety, reactogenicity, and immunogenicity of concomitant administration of Ad26.COV2.
View Article and Find Full Text PDFThe Role of Inflammatory Parameters and Antibody Seroconversion on COVID-19 Outcomes in Patients with Central Obesity.
Acta Med Indones
October 2024
1. Division of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia. 2. Metabolic Disorder, Cardiovascular and Aging Research Center, Indonesian Medical Education and Research Institute, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia..
Background: Central obesity increases the risk of developing poor outcomes of COVID-19. The pro-inflammatory state and antibody dysfunction are thought to contribute to poor outcomes; however, the evidence is unclear.
Methods: This is a cohort study among COVID-19 patients with central obesity in Dr.
Humoral and Cellular Immunity After Vaccination Against SARS-CoV-2 in Relapsing-Remitting Multiple Sclerosis Patients Treated with Interferon Beta and Dimethyl Fumarate.
Biomedicines
January 2025
Department of Neurology, Medical University of Bialystok, 15-276 Bialystok, Poland.
Background/objectives: The impact of vaccines against SARS-CoV-2 on the immunity of patients with multiple sclerosis (PwMS) is still not fully known. Further clarification could help address medical concerns related to the use of immunosuppressive and immunomodulatory medications, known as disease-modifying therapies (DMTs), in PwMS, as well as ensure adequate protection against severe outcomes of COVID-19. Therefore, the aim of our study was to evaluate the humoral and cellular immune response in PwMS treated with DMTs.
View Article and Find Full Text PDFDynamics of SARS-CoV-2 infection over two epidemic waves in Manaus, Brazil: A serological study of seven thousand blood donors.
PLoS One
January 2025
Faculdade de Medicina da Universidade de São Paulo, Instituto de Medicina Tropical, São Paulo, Brazil.
Background: Most longitudinal studies of COVID-19 incidence have used unlinked samples. The city of Manaus, Brazil, has a blood donation program which allows sample linkage, and was struck by two large COVID-19 epidemic waves between mid-2020 and early 2021.
Methods: We estimated the changing force of infection, i.
Exploring the Relationship Between Humoral and Cellular T Cell Responses Against SARS-CoV-2 in Exposed Individuals From Emilia Romagna Region and COVID-19 Severity.
HLA
January 2025
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
COVID-19 remains a significant global health problem with uncertain long-term consequences for convalescents. We investigated the relationships between anti-N protein antibody levels, severe acute respiratory syndrome (SARS)-CoV-2-associated TCR repertoire parameters, HLA type and epidemiological information from three cohorts of 524 SARS-CoV-2-infected subjects subgrouped in acute phase, seronegative and seropositive convalescents from the Emilia Romagna region. Epidemiological information and anti-N antibody index were associated with TCR repertoire data.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!